PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation

American Journal of Physiology. Heart and Circulatory Physiology
Shintaro NemotoBlase A Carabello

Abstract

Previously we reported that the beneficial effects of beta-adrenergic blockade in chronic mitral regurgitation (MR) were in part due to induction of bradycardia, which obviously affects myocardial energy requirements. From this observation we hypothesized that part of the pathophysiology of MR may involve faulty energy substrate utilization, which in turn might lead to potentially harmful lipid accumulation as observed in other models of heart failure. To explore this hypothesis, we measured triglyceride accumulation in the myocardia of dogs with chronic MR and then attempted to enhance myocardial metabolism by chronic administration of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist rosiglitazone. Cardiac tissues were obtained from three groups of dogs that included control animals, dogs with MR for 3 mo without treatment, and dogs with MR for 6 mo that were treated with rosiglitazone (8 mg/day) for the last 3 mo of observation. Hemodynamics and contractile function (end-systolic stress-strain relationship, as measured by K index) were assessed at baseline, 3 mo of MR, and 6 mo of MR (3 mo of the treatment). Lipid accumulation in MR (as indicated by oil red O staining score and TLC analysis) was marked and ...Continue Reading

References

May 1, 1992·The American Journal of Medicine·E J Eichhorn
Jan 1, 1992·Journal of Inherited Metabolic Disease·D P KellyA W Strauss
May 1, 1992·Journal of the American College of Cardiology·T J Regan, A B Weisse
Apr 11, 1989·The American Journal of Physiology·B A CarabelloJ F Spann
Jun 1, 1988·The American Journal of Physiology·J P KleavelandB A Carabello
Aug 1, 1997·Journal of the American College of Cardiology·J W SwanA J Coats
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·Y T ZhouR H Unger
Apr 4, 2001·The Journal of Clinical Investigation·H C ChiuJ E Schaffer
Dec 12, 2001·Circulation·P RazeghiH Taegtmeyer
Jul 11, 2002·Journal of the American College of Cardiology·Víctor G Dávila-RománRobert J Gropler

❮ Previous
Next ❯

Citations

Mar 23, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Yuan-Wen ChenLouis J Dell'italia
May 22, 2007·Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology·Naohito NishiiHitoshi Kitagawa
Dec 23, 2008·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·L Saccà, R Napoli
Jul 4, 2007·Hypertension·Nathan K LebrasseurFlora Sam
Jul 25, 2007·Circulation·Houman AshrafianLionel H Opie
Mar 16, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Qinglin Yang, Yuhao Li
Apr 7, 2006·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·J G LeichmanH Taegtmeyer
Apr 11, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Petra RocicPamela A Lucchesi
Dec 26, 2006·American Journal of Physiology. Lung Cellular and Molecular Physiology·Joseph T CrossnoDwight J Klemm
Mar 11, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Tomas G NeilanJudy Hung
Jul 19, 2008·Progress in Cardiovascular Diseases·Christos KassiotisHeinrich Taegtmeyer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.